FAKTOR-OPTIONSSCHEIN - INCYTE CO. Share Price

DE000SQ8HCD7

Delayed Deutsche Boerse AG 15:29:12 05/06/2024 BST
23.98 ^EUR	+4.76%

Current month	-8.99%
1 month	-47.32%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart INCYTE CORPORATION

Latest news about INCYTE CORPORATION

Incyte Completes Acquisition of Escient Pharmaceuticals	05-30	BU
Deutsche Bank Initiates Incyte to Hold Rating With $55 Price Target	05-23	MT
Incyte Acquires 2 Office Buildings in Delaware	05-21	MT
Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings	05-21	BU

More news

Quotes 5-day view

Date	Price	Change
05/06/24	23.98	+4.76%
04/06/24	22.89	+1.82%
03/06/24	22.48	-10.62%
31/05/24	25.15	-3.53%
30/05/24	26.07	-3.84%

Delayed Quote Deutsche Boerse AG

Last update June 05, 2024 at 03:29 pm

More quotes

Static data

Product type	Exotische Produkte
Buy / Sell	CALL
Underlying	INCYTE CORPORATION
Issuer	Société Générale
WKN	SQ8HCD
ISIN	DE000SQ8HCD7
Date issued	01/02/2023
Strike	83.68 $
Maturity	Unlimited
Parity	1 : 1
Emission price	10.22 €
Emission volume	N/A
Settlement	Barausgleich
Currency	EUR

Technical Indicators

Highest since issue	86.57 €
Lowest since issue	9.33 €
Spread	0.16 €
Spread %	0.67%

Company Profile

Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (85.6%); - royalties (14.2%); - income from research and cooperation agreements (0.2%).

Sector

More about the company

Ratings for Incyte Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Consensus: Incyte Corporation

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

58.57 USD

Average target price

72.8 USD

Spread / Average Target

+24.30%

Consensus